Fecal Clostridium difficile Toxin A is a key biomarker used in the diagnosis of C. difficile infection (CDI), a serious condition that commonly arises in patients undergoing prolonged antibiotic treatment. Toxin A is one of two major exotoxins produced by C. difficile, the other being Toxin B, and is known to disrupt intestinal epithelial cells, leading to inflammation, diarrhea, and colitis. Detection of Toxin A in stool specimens is crucial for confirming active infection and guiding appropriate clinical treatment.
In research and clinical settings, the Fecal C. difficile Toxin A ELISA assay provides a qualitative method for detecting the presence of Toxin A using a highly specific “sandwich” immunoassay format. This test captures the toxin directly from stool samples using immobilized monoclonal antibodies, followed by detection with HRP-conjugated tracer antibodies. The colorimetric change measured through a microplate reader reflects the level of Toxin A in the sample, allowing clinicians to confirm the presence of the pathogen’s active toxin.
Because Toxin A is an early marker of pathogenic C. difficile strains, this ELISA assay serves as a valuable tool not only in diagnosis but also in infection control studies, outbreak monitoring, and therapeutic trials. The assay’s high specificity and ease of use make it suitable for both routine clinical diagnostics and large-scale epidemiological research, helping improve patient outcomes and reduce healthcare-associated infections.
This product is manufactured in USA by Eagle Biosciences.